Caplin Point Laboratories has received approval from Brazil's National Health Surveillance Agency ANVISA (Agencia Nacional de Vigilancia Sanitaria) for its sterile injectable manufacturing site at Chennai. The facility is capable of manufacturing Liquid Injectables in Vials, Ampoules, Lyophilized Vials and Ophthalmic dosages.
The approval grants access to the company to register and market its products at the large and growing Brazilian Pharmaceutical market.
Caplin Point Laboratories is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa.
